DOI: 10.6084/m9.figshare.26568016.v1
title: Additional file 1 of Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues

description: Additional file 1: Table S1. Patient clinical data and medical treatment information. Differentially expressed genes between non-functioning PitNET and growth hormone secreting PitNET types. Table S2. Enrichment results for non-functioning PitNET and growth hormone secreting PitNET type differentially expressed genes obtained from STRING-db (v11.5) (Sorted by decreasing enrichment strength, FDR &lt; 0.05). Table S3. Summary of enrichment results for non-functioning PitNET and growth hormone secreting PitNET type from STRING-db(v11.5) (Sorted alphabetically by compartment, FDR &lt; 0.05). Table S4. Growth hormone associated enrichment results for non-functioning PitNET and growth hormone secreting PitNET type from STRING-db(v11.5). Table S5. Molecule transport channel associated enrichment results for non-functioning PitNET and growth hormone secreting PitNET type from STRING-db(v11.5) (Sorted by enrichment strength, FDR &lt; 0.05). Table S6. Protein-protein interaction matrix from non-functioning PitNET and growth hormone secreting PitNET type with interaction scores represented for each interaction type. Table S7. Detected differentially expressed genes from non-functioning PitNET and growth hormone secreting PitNET type comparison overlaping with a curated literature list of 236. Table S8. Differentially expressed genes between SSA treated/untreated somatotrophin secreting PitNET tissue groups. Table S9. Functional enrichment results for differentially expressed genes between SSA treated/untreated PitNET somatotrophin groups. Table S10. Protein-Protein interaction results for differentially expressed genes between SSA treated/untreated PitNET GH groups (FDR &lt; 0.05). Table S11. Differentially expressed genes between octreotide treated pituispheres at all time points (time-series, LRT) and untreated control (LRT, Sorted by P-adjusted values, L2FC &gt; +/- 0.58, P-adjusted &lt; 0.05). Table S12. Differentially expressed genes between cabergoline treated pituispheres at all time points (time-series, LRT) and untreated control. Table S13. Differentially expressed genes between cabergoline treated pituispheres after incubation of 8h and untreated control (Wald test, Sorted by P-adjusted values, L2FC &gt; +/- 0.58, P-adjusted &lt; 0.05). Table S14. Differentially expressed genes between cabergoline treated pituispheres at all time points (time-series, LRT) and untreated control (LRT, Sorted by P-adjusted values, L2FC &gt; +/- 0.58, P-adjusted &lt; 0.05). Table S15. Differentially expressed genes between octreotide treated pituispheres after incubation of 4h and untreated control. Table S16. Differentially expressed genes between octreotide treated pituispheres after incubation of 8h and untreated control (Wald test, Sorted by P-adjusted values, L2FC &gt; +/- 0.58, P-adjusted &lt; 0.05). Table S17. Differentially expressed genes between octreotide treated pituispheres after incubation of 24h and untreated control. Table S18. Differentially expressed genes between octreotide treated pituispheres after incubation of 48h and untreated control (Wald test, Sorted by P-adjusted values, L2FC &gt; +/- 0.58, P-adjusted &lt; 0.05). Table S19. Differentially expressed genes between octreotide treated pituispheres after incubation of 72h and untreated control (Wald test, Sorted by P-adjusted values, L2FC &gt; +/- 0.58, P-adjusted &lt; 0.05). Table S20. Differentially expressed genes between cabergoline treated pituispheres after incubation of 4h and untreated control (Wald test, Sorted by P-adjusted values, L2FC &gt; +/- 0.58, P-adjusted &lt; 0.05). Table S21. Differentially expressed genes between cabergoline treated pituispheres after incubation of 8h and untreated control. Table S22. Differentially expressed genes between cabergoline treated pituispheres after incubation of 24h and untreated control. Table S23. Differentially expressed genes between cabergoline treated pituispheres after incubation of 48h and untreated control (Wald test, Sorted by P-adjusted values, L2FC &gt; +/- 0.58, P-adjusted &lt; 0.05). Table S24. Differentially expressed genes between cabergoline treated pituispheres after incubation of 72h and untreated control (Wald test, Sorted by P-adjusted values, L2FC &gt; +/- 0.58, P-adjusted &lt; 0.05). Table S25. Functional enrichment results for differentially expressed RYR2, COL8A2 and MKI67 genes in the octreotide time-series comparison (Results sorted by decreasing enrichment strength, FDR &lt; 0.05). Table S26. Functional enrichment results for differentially expressed genes in the octreotide time-series comparison (Results sorted by decreasing enrichment strength, FDR &lt; 0.05). Table S27. Functional enrichment results for differentially expressed RYR2, COL8A2 and MKI67 genes in the cabergoline time-series comparison (Results sorted by decreasing enrichment strength, FDR &lt; 0.05). Table S28. Functional enrichment results for differentially expressed genes in the cabergoline time-series comparison (Results sorted by decreasing enrichment strength, FDR &lt; 0.05). Table S29. Differentially expressed genes between octreotide treated GH3 cells after incubation of 4h and untreated control (Wald test, Sorted by P-adjusted values, P-adjusted &lt; 0.05). Table S30. Differentially expressed genes between octreotide treated GH3 cells after incubation of 8h and untreated control (Wald test, Sorted by P-adjusted values, P-adjusted &lt; 0.05). Table S31. Differentially expressed genes between octreotide treated GH3 cells after incubation of 24h and untreated control (Wald test, Sorted by P-adjusted values, P-adjusted &lt; 0.05). Table S32. Functional enrichment results for differentially expressed genes in the GH3 24h vs GH3 control comparison (Results sorted by decreasing enrichment strength, FDR &lt; 0.05). Table S33. Protein-Protein interaction results for differentially expressed human orthologue genes between GH3 octreotide treated/untreated 24h incubation period groups (FDR &lt; 0.05). Table S34. Functional enrichment results for cabergoline treated pituispheres after incubation of 4h and untreated control (FDR &lt; 0.05). Table S35. Functional enrichment results for cabergoline treated pituispheres after incubation of 8h and untreated control (FDR &lt; 0.05). Table S36. Functional enrichment results for cabergoline treated pituispheres after incubation of 24h and untreated control (FDR &lt; 0.05). Table S37. Functional enrichment results for cabergoline treated pituispheres after incubation of 48h and untreated control. Table S38. Functional enrichment results for cabergoline treated pituispheres after incubation of 72h and untreated control (FDR &lt; 0.05). Table S39. Functional enrichment results for octreotide treated pituispheres after incubation of 8h and untreated control. Table S40. Functional enrichment results for octreotide treated pituispheres after incubation of 24h and untreated control. Table S41. Functional enrichment results for octreotide treated pituispheres after incubation of 48h and untreated control. Table S42. Functional enrichment results for octreotide treated pituispheres after incubation of 72h and untreated control (FDR &lt; 0.05).